A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis

Exclusion Criteria

• •In the opinion of the Investigator, other clinically significant lung disease (e.g. asthma, emphysema, chronic obstructive pulmonary disease, cavitary or pleural diseases, clinically significant or treatment-requiring pulmonary hypertension) at screening.
• •Interstitial lung disease (ILD) other than IPF (including, but not limited to, connective tissue diseases, vasculitis).
• •Acute IPF exacerbation within 16 weeks prior to screening and/or during the screening period (investigator-determined).
• •Lower respiratory tract infection requiring antibiotics within 4 weeks prior to screening and/or during the screening period.
• •Evidence of impaired kidney function, unstable cardiovascular disease, moderate or severe hepatic impairment or any significant disease or condition other than IPF which may interfere with trial procedures or interpretation of trial results, or cause concern regarding the patient's ability to participate in the trial or any medical condition which could lead to a life expectancy \< 12months